Johnson & Johnson completed the acquisition of Halda Therapeutics for $3.05bn.

Johnson & Johnson, a company which engages in the research and development, and manufacture and sale of products in the health care field, completed the acquisition of Halda Therapeutics, a clinical-stage biotechnology company with a proprietary platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05bn. “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines. We are excited to formally welcome the talented Halda team to Johnson & Johnson and look forward to working together to achieve our shared goal of eliminating cancer,” Jennifer Taubert, Johnson & Johnson Executive Vice President and Worldwide Chairman.